FDA approves Novartis’ Gilenya for paediatric use
admin 14th May 2018 Uncategorised 0US regulators have approved Novartis’ Gilenya to treat children and adolescents with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for this patient group.
More: FDA approves Novartis’ Gilenya for paediatric use
Source: News